Ilex Medical
VC Fund
Petah Tiqva, Israel
Ilex Medical is a VC fund in Petah Tiqva focused on Biotechnology and Medical. Ilex Medical offers a wide range of medical equipment and food and vitamin supplements.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Ilex Medical invests in
Stages Ilex Medical invests in
Countries Ilex Medical invests in
Investment Focus
Industry
- Biotechnology 2 (50%)
- Medical 1 (25%)
- Therapeutics 1 (25%)
- Medical Device 1 (25%)
- Image Recognition 1 (25%)
Stage
- Series A 1 (25%)
- Series C 1 (25%)
- Post-IPO Equity 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Starget Pharma
|
Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $18M / Series A / Feb 18, 2026 | |
Scopio Labs
|
Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio's solutions will aim to showcase thousands of cells at scale in high resolution, toenable new hematology diagnostic methods. | $50M / Series C / Feb 09, 2022 | |
|
Scopio Labs
|
Scopio Labs is a provider of Full Field Morphology dedicated to unlocking the potential of imaging and AI in hematology. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio's solutions will aim to showcase thousands of cells at scale in high resolution, toenable new hematology diagnostic methods. | $50M / Series C / Feb 09, 2022 | |
Kadimastem
|
Kadimastem is a regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The company’s proprietary technologies and know-how enable the differentiation of stem cells into insulin secreting beta cells as well as a range of neuralcells, including Oligodendrocytes and Astrocytes. Based on its differentiation technologies, the company advances two therapeutic programs focused on diabetes mellitus and ALS, where stem cells are differentiated into beta cells for the diabetes program and astrocytes are differentiated into beta cells for the ALS program, with the goal of implanting them into patients, and affecting diseases progression. The company’s technology is designed to screen compounds automatically and quantify the readouts using a cell-based High Content Screening (HCS) system. Kadimastem partners with pharmaceutical companies to screen potential drug compounds on its stem-cell derived cells. It produces a number of human cell and tissue systems that constitute screening platforms to search for agonists or antagonists of specific biological processes, with the aim of developing safe drugs.Kadimastem is based in Nes Ziona, Israel. | $3.2M / Post-IPO Equity / Nov 25, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ilex Medical invest in?
Ilex Medical invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series C stage. Most of the 4 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Ilex Medical last invest?
The most recent investment recorded for Ilex Medical closed in Feb 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
